HBK Sorce Advisory’s Aquestive Therapeutics AQST Stock Holding History

HBK Sorce Advisory’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$160K	Hold	42,547	–	–	﹤0.01%	634
2026 Q1	$184K	Buy	42,547 +1	+0%	+$4	﹤0.01%	611
2025 Q4	$175K	Sell	42,546 -99	-0.2%	-$617	﹤0.01%	599
2025 Q3	$313K	Sell	42,645 -701	-2%	-$3.03K	0.01%	465
2025 Q2	$143K	Buy	43,346 +809	+2%	+$2.32K	﹤0.01%	564
2025 Q1	$123K	Buy	42,537 +189	+0.4%	+$572	﹤0.01%	557
2024 Q4	$151K	Hold	42,348	–	–	﹤0.01%	550
2024 Q3	$211K	Hold	42,348	–	–	0.01%	532
2024 Q2	$110K	Hold	42,348	–	–	﹤0.01%	543
2024 Q1	$180K	Hold	42,348	–	–	0.01%	567
2023 Q4	$85.5K	Hold	42,348	–	–	﹤0.01%	549
2023 Q3	$64.8K	Hold	42,348	–	–	﹤0.01%	546
2023 Q2	$69.9K	Hold	42,348	–	–	﹤0.01%	568
2023 Q1	$48.3K	Buy	+42,348	New	+$36.7K	﹤0.01%	569

Other funds holding AQST

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

EAM

Everstar Asset Management Mooresville, North Carolina $207M AUM 18.14% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

HBK Sorce Advisory's AQST Position: Q2 2026 in Review

HBK Sorce Advisory held its Aquestive Therapeutics (AQST) position steady in Q2 2026 at 42,547 shares worth $160K. The position accounts for ﹤0.01% of the portfolio, ranked #634.

HBK Sorce Advisory first reported a position in AQST in Q1 2023 and has held it in 14 quarters since. The position peaked at $313K in Q3 2025. 69 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

HBK Sorce Advisory held 42,547 shares of Aquestive Therapeutics worth $160K as of Q2 2026.
HBK Sorce Advisory left its Aquestive Therapeutics share count unchanged in Q2 2026.
Aquestive Therapeutics made up ﹤0.01% of HBK Sorce Advisory's portfolio in Q2 2026, its #634 holding.
HBK Sorce Advisory first reported a position in Aquestive Therapeutics in Q1 2023 and has held it in 14 quarters since.
HBK Sorce Advisory's Aquestive Therapeutics position peaked at $313K in Q3 2025.
69 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on HBK Sorce Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.